Emaretamig

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, emaretamig simultaneously binds to both CLDN18.2-expressing tumor cells and CD3-expressing T-cells, thereby crosslinking CLDN18.2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.

**Synonyms:** - ASP 2138 - ASP-2138 - ASP2138 - Anti-CLDN18.2/Anti-CD3 Bispecific Antibody ASP2138 - Anti-Claudin18.2/Anti-CD3 Bispecific Antibody ASP2138 - Anti-Claudin18.2/CD3 Bispecific Antibody ASP2138 - Claudin18.2 x CD3 Bispecific Antibody ASP2138 - EMARETAMIG